OPKO and Pfizer Receive Regulatory Clearance for Global Agreement

OPKO Health, Inc. and Pfizer Inc. announced the closing of their worldwide agreement for the development and commercialization of hGH-CTP, a long-acting human growth hormone. The closing follows termination of the waiting period under the Hart-Scott Rodino Act.